Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05067348 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis

Study acronym: tMG
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 1, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Mar 31, 2024 to Dec 31, 2025
    • Study completion date: Sep 30, 2024 to Mar 30, 2026
    v7
  2. Re-verified, no change to tracked fieldsv6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 15, 2022 to Jul 21, 2022
    • Site details revised at 6 of 6 sites
    v5
  4. Start date: Nov 30, 2021 to Jun 15, 2022
    • Study sites: 5 to 6
    v4
  5. Start date: Oct 8, 2021 to Nov 30, 2021v3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension.
Trial Details
NCT Number NCT05067348
Lead Sponsor Tang-Du Hospital
Conditions
(from sponsor)		 Myasthenia Gravis, Generalized
Related terms Myasthenia Gravis
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov